ArticleThe European respiratory journal2022
Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation.
Article in The European respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- The Complement System and Its Role in Eosinophilic Inflammation in Respiratory Diseases.Biomedicines · 2026Review
- Multicellular crosstalk in neutrophilic asthma: unraveling the pathogenic web of steroid resistance and emerging precision therapies.Journal of translational medicine · 2026Review
- Article
- Asthma endotypes and theratypes.Chinese medical journal pulmonary and critical care medicine · 2026Review
- The identification of biomarkers for response to omalizumab in adult asthma based on untargeted metabolomic analysis.Medicine · 2026Article
- Impact of clinical factors and season on inflammatory cytokines in biologic-treated and untreated asthma.Respiratory research · 2025Article
- Airway sympathectomy attenuates inflammation, transcriptional ratios of Muc5ac and Muc5b, and airway mechanic deficits in mice delivered intranasal IL-13.American journal of physiology. Lung cellular and molecular physiology · 2025Article
- Article
- C-BIOPRED severe asthma clinical phenotypes: link to complement and coagulation pathways and galectin 10.ERJ open research · 2025Article
- Review
- Advances in non-type 2 severe asthma: from molecular insights to novel treatment strategies.The European respiratory journal · 2024Review
- Role of Complement Components in Asthma: A Systematic Review.Journal of clinical medicine · 2024Review
- Role and regulators of NFrontiers in pharmacology · 2024Review
- Consensus clustering with missing labels (ccml): a consensus clustering tool for multi-omics integrative prediction in cohorts with unequal sample coverage.Briefings in bioinformatics · 2023Article
- Antioxidant Intake and Biomarkers of Asthma in Relation to Smoking Status-A Review.Current issues in molecular biology · 2023Review
- Promising treatment biomarkers in asthma.Frontiers in drug safety and regulation · 2023Review
- Reply: U-BIOPRED/BIOAIR proteins: inflammation or infection?The European respiratory journal · 2022Article
- Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment.Biomedicines · 2022Article
- Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
50 authors at 20 institutions in 13 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleAsthma phenotyping requires novel biomarker discovery.
objectivesTo identify plasma biomarkers associated with asthma phenotypes by application of a new proteomic panel to samples from two well-characterised cohorts of severe (SA) and mild-to-moderate (MMA) asthmatics, COPD subjects and healthy controls (HCs).
methodsAn antibody-based array targeting 177 proteins predominantly involved in pathways relevant to inflammation, lipid metabolism, signal transduction and extracellular matrix was applied to plasma from 525 asthmatics and HCs in the U-BIOPRED cohort, and 142 subjects with asthma and COPD from the validation cohort BIOAIR. Effects of oral corticosteroids (OCS) were determined by a 2-week, placebo-controlled OCS trial in BIOAIR, and confirmed by relation to objective OCS measures in U-BIOPRED.
resultsIn U-BIOPRED, 110 proteins were significantly different, mostly elevated, in SA compared to MMA and HCs. 10 proteins were elevated in SA
conclusionsThe plasma proteomic panel revealed previously unexplored yet potentially useful Type-2-independent biomarkers and validated several proteins with established involvement in the pathophysiology of SA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.